DRG® GLP-1 (total)   (EIA-5095)

RUO

Revised 9 Mar. 2011 rm (Vers. 3.0)

Please use only the valid version of the package insert provided with the kit.

1   INTENDED USE

This ELISA (enzyme-linked immunosorbent assay) kit is produced for the quantitative determination of the total value of glucagon-like peptide-1 (7-36) [GLP-1 (7-36)] and (9-36) [GLP-1 (9-36)] in plasma samples. The primary amino acid sequence of GLP-1 peptide is identical among mammalian species, i.e. rat, mouse, pig, human, etc. ***This kit is for research purpose only.***

2   ASSAY PRINCIPLE

This ELISA is designed, developed and produced for the quantitative measurement of GLP-1 (7-36) and (9-36) in plasma sample. The assay utilizes the two-site "sandwich" technique with two selected GLP-1 antibodies.

Assay standards, controls and test samples are directly added to wells of a microplate that is coated with streptavidin. Subsequently, a mixture of biotinylated GLP-1 specific antibody and a horseradish peroxidate (HRP) conjugated GLP-1 specific antibody is added to each well. After the first incubation period, a "sandwich" immunocomplex of "Streptavidin – Biotin-Antibody – GLP-1(7-36)/(9-36) – HRP conjugated antibody" is formed and attached to the wall of the plate. The unbound HRP conjugated antibody is removed in a subsequent washing step. For the detection of this immunocomplex, each well is then incubated with a substrate solution in a timed reaction and then measured in a spectrophotometric microplate reader. The enzymatic activity of the immunocomplex bound to GLP-1 (7-36)/(9-36) on the wall of the microtiter well is directly proportional to the amount of Total GLP-1 in the sample.

3   REAGENTS: PREPARATION AND STORAGE

This test kit must be stored at $2 – 8°C$ upon receipt. For the expiration date of the kit refer to the label on the kit box. All components are stable until this expiration date.

Prior to use allow all reagents to come to room temperature. Regents from different kit lot numbers should not be combined or interchanged.

1.   Streptavidin Coated Microplate
One well-breakable microplate with 12 x eight strips (96 wells total) coated with streptavidin. The plate is framed and sealed in a foil zipper bag with a desiccant. This reagent should be stored at $2 – 8°C$ and is stable until the expiration date on the kit box.

2.   Total GLP-1 Tracer Antibody
One vial containing 0.6 mL HRP labeled Anti-GLP-1 specific antibody in a stabilized protein matrix. This reagent must be mixed with Total GLP-1 Capture Antibody and the tracer antibody diluent before use (for details see Assay Procedure). This reagent should be stored at $2 – 8°C$ and is stable until the expiration date on the kit box.

Revised 9 Mar. 2011 rm (Vers. 3.0)

3. Total GLP-1 Capture Antibody
One vial containing 0.6 mL of biotinylated Total GLP-1 specific antibody. It should be used only after mixed with Total GLP-1 Tracer Antibody and the tracer antibody diluent according to the assay procedures. This reagent should be stored at 2 – 8°C and is stable until the expiration date on the kit box.

4. ELISA Wash Concentrate
One bottle contains 20 mL of 30 fold concentrate. Before use the contents must be diluted with 580 mL of distilled water and mixed well. Upon dilution this yields a working wash solution containing a surfactant in phosphate buffered saline with a non-azide and non-mercury based preservative. The diluted wash buffer should be stored at room temperature and is stable until the expiration date on the kit box.

5. ELISA HRP Substrate
One bottle contains 24 mL of tetramethylbenzidine (TMB) with stabilized hydrogen peroxide. This reagent should be stored at 2 – 8°C and is stable until the expiration date on the kit box.

6. ELISA Stop Solution
One bottle contains 12 mL of sulfuric acid. This reagent should be stored at 2 – 8°C or room temperature and is stable until the expiration date on the kit box.

7. GLP-1 Standards
Five vials containing different levels of lyophilized GLP-1 (7-36) in a liquid protein matrix with a non-azide, non-mercury based preservative. **Refer to vial for exact concentration for each standard.** These reagents should be stored at 2 – 8°C and are stable until the expiration date on the kit box.

8. GLP-1 Controls
Two vials containing different levels of lyophilized GLP-1 (7-36) in a liquid protein matrix with a non-azide, non-mercury based preservative. **Refer to vials for exact concentration range for each control.** Both controls should be stored at 2 – 8°C and are stable until the expiration date on the kit box.

9. Tracer Antibody Diluent
One vial containing 12 mL ready to use buffer. It should be used only for tracer antibody dilution according to the assay procedures. This reagent should be stored at 2 – 8°C and is stable until the expiration date on the kit box.

4   SAFTY PRECAUTIONS
The reagents must be used in a professional laboratory environment and are for research use only. Source material (e.g. highly purified bovine serum albumin) of bovine serum was derived in the contiguous 48 United States. It was obtained only from donor healthy animals maintained under veterinary supervision and found free of contagious diseases. Wear gloves while performing this assay and handle these reagents as if they are potential infectious. Avoid contact with reagents containing TMB, hydrogen peroxide, or sulfuric acid. TMB may cause irritation to skin and mucous membranes and cause an allergic skin reaction. TMB is a suspected carcinogen. Sulfuric acid may cause sever irritation on contact with skin. Do not get in eyes, on skin, or on clothing. Do not ingest or inhale fumes. On contact, flush with copious amounts of water for at least 15 minutes. Use Good Laboratory Practices.

Revised 9 Mar. 2011 rm (Vers. 3.0)

5   MATERIALS REQUIRED BUT NOT PROVIDED

1. Precision single channel pipettes capable of delivering 25 µL, 50 µL, 100 µL, and 1000 µL etc.
2. Repeating dispenser suitable for delivering 100 µL.
3. Disposable pipette tips suitable for above volume dispensing.
4. Disposable 12 x 75 mm or 13 x 100 glass/plastic tubes.
5. Disposable plastic 100 mL and 1000 mL bottle with caps.
6. Aluminum foil.
7. Deionized or distilled water.
8. Plastic microtiter well cover or polyethylene film.
9. ELISA plate shaker
10. ELISA multichannel wash bottle or automatic (semi-automatic) washing system.
11. Spectrophotometric microplate reader capable of reading absorbance at 450 nm.
12. DPP-4 Inhibitor

6   SPECIMEN COLLECTION

(1) No special preparation of individual is necessary prior to specimen collection. However, fasting sample and non-fasting/glucose induced sample may present great significance for Total GLP-1 level.

(2) Both BD™ P700 Blood Collection and Preservation System (contains a DPP-4 protease inhibitor cocktail) and lavender top Vacutainer® EDTA-plasma tube can be used for sample collection.

(3) If the Vacutainer® EDTA-plasma tube is used for sample collection, it is recommended (but not necessary) to add appropriate amount of DPP-4 inhibitor to the collected EDTA whole blood right after the collection. Refer to DPP-4 inhibitor manufacturer's instruction. Invert tube to mix well and place the tube on ice bath. Centrifuge the tube at 1000 g for 10 minutes in a refrigerated centrifuge.
Note: since sample with DPP-4 inhibitor is strongly recommended for measurement of Active GLP-1 (7-36), the DPP-4 inhibitor should be included in sample collection if the same sample will be used for both Active GLP-1 (7-36) and Total GLP-1 measurement.

(4) Plasma samples should be stored at 2 – 8°C if they will be tested within 3 hours of collection. For longer storage, it is recommended to store the plasma sample at -70°C. Aliquot samples before freezing if necessary.

Revised 9 Mar. 2011 rm (Vers. 3.0)

7   ASSAY PROCEDURE

7.1   Reagent Preparation

(1) Prior to use allow all reagents to come to room temperature. Regents from different kit lot numbers should not be combined or interchanged.

(2) ELISA Wash Concentrate must be diluted to working solution prior use. Please see REAGENTS section for details.

(3) Reconstitute all standards and controls by adding **1.0 mL** of deminerialized water to each vial. Allow the standards and controls to sit undisturbed for 10 minutes, and then mix well by gentle vortexing. These reconstituted standards and controls must be stored at - 20°C or below. Do not exceed 3 freeze-thaw cycles.

7.2   Test Sample Preparation

EDTA-plasma samples with or without DPP-IV inhibitor can be directly measured for the Total GLP-1 concentration.

If a pre-assay sample extraction procedure is desired, we recommend using a solid phase sample extraction procedure with a GLP-1 Sample Extraction Kit (Cat# KT-910).

7.3   Assay Procedure

(1) Place a sufficient number of streptavidin coated microwell strips/wells in a holder to run Total GLP-1 standards, controls and unknown samples in duplicate.

(2) Test Configuration

ROW	STRIP 1	STRIP 2	STRIP 3
A	STD 1	STD 5	SAMPLE 2
B	STD 1	STD 5	SAMPLE 2
C	STD 2	C 1	SAMPLE 3
D	STD 2	C 1	SAMPLE 3
E	STD 3	C 2	SAMPLE 4
F	STD 3	C 2	SAMPLE 4
G	STD 4	SAMPLE 1	
H	STD 4	SAMPLE 1	

(3) Prepare Total GLP-1 Antibody Mixture: mixing Total GLP-1 Tracer Antibody and Total GLP-1 Capture Antibody by 1:21 fold dilution of the Tracer Antibody and by 1:21 fold dilution of the biotinylated Capture Antibody with the Tracer antibody Diluent.
For each strip, it is required to mix 1 mL of the Tracer Antibody Diluent with 50 μL the Capture Antibody and 50 μL of the Tracer Antibody in a clean test tube.

(4) Add **100 μL** of standards, controls and test samples into the designated microwell.

(5) Add **100 μL** of Total GLP-1 Antibody Mixture to each well

(6) Cover the plate with one plate sealer and incubate plate at 2-8°C, static for **20 - 24 hours**.

Revised 9 Mar. 2011 rm (Vers. 3.0)

(7) Remove plate sealer. Aspirate the contents of each well. Wash each well 5 times by dispensing 350 µL of working wash solution into each well and then completely aspirating the contents. Alternatively, an automated microplate washer can be used.

(8) Add **200 µL** of ELISA HRP Substrate into each of the wells.

(9) Cover the plate with one plate sealer and also with aluminum foil to avoid exposure to light.

(10) Incubate plate at room temperature, static for **20 min**.

(11) Remove the aluminum foil and plate sealer. Add **50 µL** of ELISA Stop Solution into each of the wells. Mix gently.

(12) Read the absorbance at wavelength **450 nm/620 nm** or **450 nm/650 nm** within 10 minutes in a microplate reader

8   PROCEDURAL NOTES

1. It is recommended that all standards, controls and unknown samples be assayed in duplicate. The average absorbance reading of each duplicate should be used for data reduction and the calculation of results.

2. For samples with higher than standard level 5, it is recommended to measure diluted specimen with an appropriate GLP-1 free human plasma matrix or an appropriate buffer matrix (e.g. standard zero) for a more accurate report.

3. Keep light sensitive reagents in the original amber bottles.

4. Store any unused streptavidin coated strips in the foil zipper bag with desiccant to protect from moisture.

5. Careful technique and use of properly calibrated pipetting devices are necessary to ensure reproducibility of the test.

6. Incubation times or temperatures other than those stated in this insert may affect the results.

7. Avoid air bubbles in the microwell as this could result in lower binding efficiency and higher CV% of duplicate reading.

8. All reagents should be mixed gently and thoroughly prior use. Avoid foaming.

9   INTERPRETATION OF RESULTS

1. Calculate the average absorbance for each pair of duplicate test results.

2. Subtract the average absorbance of the STD 1 (0 ng/mL) from the average absorbance of all other readings to obtain corrected absorbance.

3. The standard curve is generated by the corrected absorbances of all standard levels on the ordinate against the standard concentration on the abscissa using point-to-point or log-log paper. Appropriate computer assisted data reduction programs may also be used for the calculation of results. We recommend using **Point-to-Point** or **Quadratic** curve fit.

The GLP-1 (7-36) concentrations for the controls and test samples are read directly from the standard curve using their respective corrected absorbance. If log-log graphic paper or computer assisted data reduction program utilizing logarithmic transformation are used, sample having corrected absorbance between the 2nd standard and the next highest standard should be calculated by the formula:

Revised 9 Mar. 2011 rm (Vers. 3.0)

$$\text{Value of unknown} = \frac{\text{Corrected absorbance (unknown)}}{\text{Corrected Absorbance (2}^{nd}\text{ STD)}} \times \text{Value of the 2}^{nd}\text{ STD}$$

## 10 EXAMPLE DATA AND STANDARD CURVE

A typical absorbance data and the resulting standard curve from this Total GLP-1 ELISA are represented.

The example curve was generated using point-to-point curve fit with linear axes. Other curve fits using linear or logarithmic axes may also be used.

This example curve should not be used in lieu of standard curve run with each assay.

Well I.D.	OD 450 nm Absorbance			Results pmol/L
	Readings	Average	Corrected	
0 pmol/L	0.091 0.102	0.096	0.000	
2.1 pmol/L	0.235 0.235	0.235	0.139	
6.0 pmol/L	0.501 0.499	0.500	0.404	
17.3 pmol/L	1.446 1.076	1.261	1.165	
54.0 pmol/L	3.123 3.107	3.115	3.019	
Control I	0.374 0.373	0.374	0.278	4.1
Control II	1.019 1.020	1.020	0.924	13.7

Revised 9 Mar. 2011 rm (Vers. 3.0)

Total GLP-1 ELISA

11 EXPECTED VALUES

Each laboratory should establish it own normal range by using samples collected from normal healthy people. Please be note that the normal range is variable by using fasting samples vs. non-fasting samples. The table indicated that the fed total GLP-1 level is higher than fasting Total GLP-1 level from normal subjects.

Donor#	Total GLP-1, pmol/L	
	Fasting	**Fed**
1	4.94	6.04
2	12.04	15.09
3	10.31	13.43
4	0.85	2.1
5	0.25	3.93
6	2.09	6.46
7	0.52	1.55
8	18.53	19.04
9	15.87	24.72
10	1.12	4.92

Based on limited number of normal donor samples (n=10), we found the fasting normal range is about 0.3 – 18.5 pmol/L and the fed normal range is about 2.1 – 24.7 pmol/L.

RUO

Revised 9 Mar. 2011 rm (Vers. 3.0)

12 LIMITATION OF THE PROCEDURE

1. Since there is no Gold Standard concentration or international standard available for Total GLP-1 measurement, the values of assay standards were established using a highly purified GLP-1 (7-36) peptide and validated by DRG. Results obtained with different assay methods or kits cannot be used interchangeably.

2. For unknown sample value read directly from the assay that is greater than assay standard level-5, it is recommend measuring a diluted sample for more accurate measurement.

3. Bacterial or fungal contamination of plasma specimens or reagents, or cross contamination between reagents may cause erroneous results.

4. Water deionized with polyester resins may inactivate the horseradish peroxidase enzyme.

13 QUALITY CONTROL

To assure the validity of the results each assay should include adequate controls with known GLP-1 (7-36) or (9-36) levels.

14 PERFORMANCE CHARACTERISTICS

14.1 Sensitivity

The sensitivity of this Total GLP-1 ELISA as determined by 3 times the standard deviation above zero standard on 12 replicate determinations is approximately 0.6 pmol/L.

14.2 Specificity

This Bioactive GLP-1 (7-36) assay is specific measure GLP-1 (7-36). It is expected that this assay does not detect following peptides.

GLP-1 (7-36)   100%

GLP-1 (9-36)   100%

GLP-1 (9-37)   < 0.1%

GLP-1 (7-37)   < 0.1%

GLP-1 (1-36)   < 0.1%

GLP-2   < 0.1%

Glucagon   < 0.1%

14.3 Precision

The intra-assay precision was determined by 8 replicates for two control samples in a single assay. A very satisfactory within assay CV% was obtained as indicated below.

#	Average GLP-1 (7-36) (n = 8)	SD	CV
Sample 1	3.02 pmol/L	0.11	3.7%
Sample 2	10.20 pmol/L	0.48	4.7%

Revised 9 Mar. 2011 rm (Vers. 3.0)

The inter assay precision was determined by 8 individual assays in different dates with two control samples. A satisfactory between assay CV% was observed as indicated below.

#	Average Total GLP-1 (n = 8)	SD	CV
Sample 1	4.16 pmol/L	0.26	6.2%
Sample 2	12.58 pmol/L	1.20	9.5%

14.4   Linearity

Two samples were diluted 1;2, 1:4 and 1:8 with GLP-1 zero standard matrix. These diluted samples are measured in this assay and the linear recovery is calculated to be 91.2% to 102%.

14.5   Spike Recovery

Patient samples were spiked each other in the sample volume (200 μl + 200 μl) and measured with this assay. The spike recovery is calculated to be 114% to 120%.

15   WARRANTY

This product is warranted to perform as described in its labeling and literature when used in accordance with all instructions. DRG. DISCLAIMS ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, and in no event shall DRG. be liable for consequential damages. Replacement of the product or refund of the purchase price is the exclusive remedy for the purchaser. This warranty gives you specific legal rights and you may have other rights, which vary from state to state.

Revised 9 Mar. 2011 rm (Vers. 3.0)

16   REFERENCES / LITERATURE

1.   Levy JC. Therapeutic intervention in the GLP-1 pathway in Type 2 diabetes.
     Diabet Med. 2006 Mar;23 Suppl 1:14-9.

2.   Mannucci E, Ognibene A, Cremasco F, Bardini G, Mencucci A, Pierazzuoli E, Ciani S, Fanelli A, Messeri G, Rotella CM. Glucagon-like peptide (GLP)-1 and leptin concentrations in obese patients with Type 2 diabetes mellitus. Diabet Med. 2000 Oct;17(10):713-9.

3.   Nauck MA, Weber I, Bach I, Richter S, Orskov C, Holst JJ, Schmiegel W. Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in type 2 diabetic patients. Diabet Med. 1998 Nov;15(11):937-45.

4.   Byrne MM, Göke B. Human studies with glucagon-like-peptide-1: potential of the gut hormone for clinical use.

5.   Mannucci E, Tesi F, Bardini G, Ognibene A, Petracca MG, Ciani S, Pezzatini A, Brogi M, Dicembrini I, Cremasco F, Messeri G, Rotella CM. Effects of metformin on glucagon-like peptide-1 levels in obese patients with and without Type 2 diabetes. Diabetes Nutr Metab. 2004 Dec;17(6):336-42.

17   SHORT ASSAY PROTOCOL

−   Add 100 µL/well of standards, control and patient sample

−   Add 100 µL of Antibody Mixture

−   Incubate 20 - 24 hour at 2-8°C, static

−   Wash strips with diluted wash buffer

−   Add 200 µL/well of TMB substrate

−   Incubate 20 min at RT, static

−   Add 100 µL stop solution

−   Read strips at OD 450 nm/620 nm or 450 nm/650 nm

Revised 9 Mar. 2011 rm (Vers. 3.0)

SYMBOLS USED WITH DRG ASSAYS

Symbol	English	Deutsch	Français	Español	Italiano
	Consult instructions for use	Gebrauchsanweisung beachten	Consulter les instructions d'utilisation	Consulte las instrucciones de uso	Consultare le istruzioni per l'uso
CE	European Conformity	CE-Konfirmitäts-kennzeichnung	Conformité aux normes européennes	Conformidad europea	Conformità europea
IVD	In vitro diagnostic device	In-vitro-Diagnostikum	Usage Diagnostic in vitro	Para uso Diagnóstico in vitro	Per uso Diagnostica in vitro
RUO	For research use only	Nur für Forschungszwecke	Seulement dans le cadre de recherches	Sólo para uso en investigación	Solo a scopo di ricerca
REF	Catalogue number	Katalog-Nr.	Numéro de catalogue	Número de catálogo	Numero di Catalogo
LOT	Lot. No. / Batch code	Chargen-Nr.	Numéro de lot	Número de lote	Numero di lotto
$\bigtriangledown$	Contains sufficient for <n> tests/	Ausreichend für "n" Ansätze	Contenu suffisant pour "n" tests	Contenido suficiente para <n> ensayos	Contenuto sufficiente per "n" saggi
	Storage Temperature	Lagerungstemperatur	Température de conservation	Temperatura de conservación	Temperatura di conservazione
	Expiration Date	Mindesthaltbarkeits-datum	Date limite d'utilisation	Fecha de caducidad	Data di scadenza
	Legal Manufacturer	Hersteller	Fabricant	Fabricante	Fabbricante
Distributed by	Distributor	Vertreiber	Distributeur	Distribuidor	Distributore
Content	Content	Inhalt	Conditionnement	Contenido	Contenuto
Volume/No.	Volume / No.	Volumen/Anzahl	Volume/Quantité	Volumen/Número	Volume/Quantità

Version 2011-02-18~rm